134 related articles for article (PubMed ID: 22994875)
1. Tighter control of postprandial hyperglycemia with mitiglinide/voglibose fixed-dose combination in Japanese patients with type 2 diabetes mellitus.
Inoue M
Expert Opin Pharmacother; 2012 Nov; 13(16):2257-68. PubMed ID: 22994875
[TBL] [Abstract][Full Text] [Related]
2. Mitiglinide/voglibose fixed-dose combination improves postprandial glycemic excursions in Japanese patients with type 2 diabetes mellitus.
Ono Y; Kameda H; Cho KY
Expert Opin Pharmacother; 2013 Mar; 14(4):361-70. PubMed ID: 23414242
[TBL] [Abstract][Full Text] [Related]
3. Glycemic/metabolic responses to identical meal tolerance tests at breakfast, lunch and dinner in Japanese patients with type 2 diabetes mellitus treated with a dipeptidyl peptidase-4 inhibitor and the effects of adding a mitiglinide/voglibose fixed-dose combination.
Ono Y; Kamoshima H; Nakamura A; Nomoto H
Expert Opin Pharmacother; 2014 Sep; 15(13):1785-95. PubMed ID: 25046055
[TBL] [Abstract][Full Text] [Related]
4. The glycemic/metabolic responses to meal tolerance tests at breakfast, lunch and dinner, and effects of the mitiglinide/voglibose fixed-dose combination on postprandial profiles in Japanese patients with type 2 diabetes mellitus.
Ono Y; Nakamura A; Cho KY; Nomoto H
Expert Opin Pharmacother; 2014 Feb; 15(3):311-24. PubMed ID: 24328511
[TBL] [Abstract][Full Text] [Related]
5. Effects of sitagliptin or mitiglinide as an add-on to acarbose on daily blood glucose fluctuations measured by 72 h subcutaneous continuous glucose monitoring in Japanese patients with type 2 diabetes: a prospective randomized study.
Osonoi T; Saito M; Tamasawa A; Ishida H; Osonoi Y
Expert Opin Pharmacother; 2014 Jul; 15(10):1325-35. PubMed ID: 24866329
[TBL] [Abstract][Full Text] [Related]
6. Comparative effects of fixed-dose mitiglinide/voglibose combination and glimepiride on vascular endothelial function and glycemic variability in patients with type 2 diabetes: A randomized controlled trial.
Tanaka K; Okada Y; Umezu S; Hashimoto R; Tomoyose Y; Tateyama R; Hori Y; Saito M; Tokutsu A; Sonoda S; Uemura F; Kurozumi A; Tanaka Y
J Diabetes Investig; 2024 Apr; 15(4):449-458. PubMed ID: 38149694
[TBL] [Abstract][Full Text] [Related]
7. Differences between Mitiglinide/Voglibose Fixed-dose Combination and Glimepiride in Modifying Low-density Lipoprotein Heterogeneity in Japanese Type-2 Diabetic Patients: A Pilot Study.
Tani S; Nagao K; Hirayama A
Drug Res (Stuttg); 2016 Feb; 66(2):94-9. PubMed ID: 26011816
[TBL] [Abstract][Full Text] [Related]
8. Cross-Over Study Comparing Postprandial Glycemic Increase After Addition of a Fixed-Dose Mitiglinide/Voglibose Combination or a Dipeptidyl Peptidase-4 Inhibitor to Basal Insulin Therapy in Patients with Type 2 Diabetes Mellitus.
Ihana-Sugiyama N; Yamamoto-Honda R; Sugiyama T; Tsujimoto T; Kakei M; Noda M
Med Sci Monit Basic Res; 2017 Feb; 23():36-44. PubMed ID: 28242866
[TBL] [Abstract][Full Text] [Related]
9. Comparison of the hypoglycemic effect of sitagliptin versus the combination of mitiglinide and voglibose in drug-naïve Japanese patients with type 2 diabetes.
Ohta A; Ohshige T; Sakai K; Nakamura Y; Tenjin A; Tsukiyama S; Terashima Y; Matsubara F; Kawata T; Nagai Y; Tanaka Y
Expert Opin Pharmacother; 2013 Dec; 14(17):2315-22. PubMed ID: 24079645
[TBL] [Abstract][Full Text] [Related]
10. Comparison of the Efficacy of Repaglinide Versus the Combination of Mitiglinide and Voglibose on Glycemic Variability in Japanese Patients with Type 2 Diabetes.
Okada H; Tanaka M; Hasegawa G; Nakajima H; Kadono M; Okada Y; Hirata A; Oyamada H; Yamane T; Fukui M
Curr Pharm Des; 2020; 25(43):4600-4605. PubMed ID: 31538887
[TBL] [Abstract][Full Text] [Related]
11. Additive postprandial glucose-lowering effects of mitiglinide and sitagliptin in patients with type 2 diabetes mellitus.
Jung JA; Kaku K; Kim JH; Kim JR; Ko JW; Lee SY; Huh W
Adv Ther; 2013 Nov; 30(11):1018-29. PubMed ID: 24249434
[TBL] [Abstract][Full Text] [Related]
12. Glucose excursions and hypoglycemia in patients with type 2 diabetes treated with mitiglinide/voglibose versus glimepiride: A randomized cross-over trial.
Fujimoto K; Shibayama Y; Yamaguchi E; Honjo S; Hamasaki A; Hamamoto Y
J Diabetes; 2018 Aug; 10(8):675-682. PubMed ID: 29493100
[TBL] [Abstract][Full Text] [Related]
13. Comparison Between Effectiveness of 100 mg/day Sitagliptin and a Switch to Mitiglinide Calcium Hydrate/Voglibose from 50 mg/day Sitagliptin in Patients with Type 2 Diabetes.
Arao T; Okada Y; Torimoto K; Sugai K; Otsuka T; Kurozumi A; Tanaka Y
J UOEH; 2017; 39(1):1-9. PubMed ID: 28331117
[TBL] [Abstract][Full Text] [Related]
14. A prospective, randomized, multicenter trial comparing the efficacy and safety of the concurrent use of long-acting insulin with mitiglinide or voglibose in patients with type 2 diabetes.
Son JW; Lee IK; Woo JT; Baik SH; Jang HC; Lee KW; Cha BS; Sung YA; Park TS; Yoo SJ; Yoon KH
Endocr J; 2015; 62(12):1049-57. PubMed ID: 26411328
[TBL] [Abstract][Full Text] [Related]
15. Combination therapy with mitiglinide and voglibose improves glycemic control in type 2 diabetic patients on hemodialysis.
Abe M; Okada K; Maruyama T; Maruyama N; Matsumoto K
Expert Opin Pharmacother; 2010 Feb; 11(2):169-76. PubMed ID: 20025554
[TBL] [Abstract][Full Text] [Related]
16. Therapeutic efficacy of mitiglinide combined with once daily insulin glargine after switching from multiple daily insulin regimen of aspart insulin and glargine in patients with type 2 diabetes mellitus.
Yoshihara T; Kumashiro N; Kanazawa Y; Mita T; Sakurai Y; Kawai J; Abe M; Motojima K; Hara K; Yamazaki Y; Kanazawa A; Miwa S; Sato F; Kanno R; Shimizu T; Sakai K; Uchino H; Watada H; Tanaka Y; Kawamori R; Hirose T
Endocr J; 2006 Feb; 53(1):67-72. PubMed ID: 16543674
[TBL] [Abstract][Full Text] [Related]
17. Efficacy of mitiglinide and sitagliptin, alone or in combination, on postprandial excursion and glycemic variability assessed by continuous glucose monitoring: a post hoc analysis with single-day treatment.
Baek JH; Jin SM; Kaku K; Jung JA; Kim JR; Ko JW; Kim MJ; Lee SY; Huh WS; Kim JH
Expert Opin Pharmacother; 2015 Jun; 16(8):1127-36. PubMed ID: 25881690
[TBL] [Abstract][Full Text] [Related]
18. The proinsulin/insulin (PI/I) ratio is reduced by postprandial targeting therapy in type 2 diabetes mellitus: a small-scale clinical study.
Ohkura T; Inoue K; Fujioka Y; Nakanishi R; Shiochi H; Sumi K; Yamamoto N; Matsuzawa K; Izawa S; Ohkura H; Kato M; Yamamoto K; Taniguchi S
BMC Res Notes; 2013 Nov; 6():453. PubMed ID: 24215809
[TBL] [Abstract][Full Text] [Related]
19. Concomitant use of miglitol and mitiglinide as initial combination therapy in type 2 diabetes mellitus.
Tatsumi F; Hashiramoto M; Hirukawa H; Kimura T; Shimoda M; Tawaramoto K; Kanda-Kimura Y; Anno T; Kawasaki F; Mune T; Matsuki M; Kaku K
Diabetes Res Clin Pract; 2013 Jul; 101(1):35-44. PubMed ID: 23711593
[TBL] [Abstract][Full Text] [Related]
20. Comparing postprandial efficacy in type 2 diabetic patients receiving mitiglinide and sitagliptin by using continuous glucose monitoring: a pilot study.
Ando K; Nishimura R; Seo C; Tsujino D; Sakamoto M; Utsunomiya K
Expert Opin Pharmacother; 2014 Dec; 15(17):2479-85. PubMed ID: 25327311
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
